| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
As a deuterium-labeled compound, bis(1,3-dichloro-2-propyl) phosphate-d10 does not have a specific biological target. Its non-deuterated form, BDCPP, is a metabolite of organophosphate flame retardants and does not exert direct pharmacological effects. However, organophosphate esters are known to interact with various biological systems, including the endocrine system and neurotransmitter pathways. BDCPP has been detected as a urinary biomarker of exposure to TDCPP and other flame retardants. The labeled compound serves as an internal standard for the quantification of these environmental contaminants in biological and environmental samples.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
The deuterated compound itself does not possess in vitro biological activity, as it is an analytical standard. Its non-deuterated form, BDCPP, is used as a biomarker for exposure to organophosphate flame retardants. In vitro studies have shown that organophosphate flame retardants and their metabolites can affect cell viability, induce oxidative stress, and interfere with hormonal signaling pathways. However, BDCPP is primarily studied as an environmental contaminant rather than a pharmacologically active agent. The labeled compound is used to accurately quantify BDCPP levels in biological matrices. |
| ln Vivo |
Bis(1,3-dichloro-2-propyl) phosphate-d10 does not have in vivo biological activity and is not used for therapeutic purposes. Its non-deuterated form, BDCPP, is a urinary metabolite of the flame retardant TDCPP and serves as a biomarker of human exposure. Epidemiological studies have investigated the association between BDCPP levels and various health outcomes, including hormone levels and reproductive health. The labeled compound is used as an internal standard in these studies to ensure accurate quantification of BDCPP in urine and other biological samples.
|
| Enzyme Assay |
In vitro assays for bis(1,3-dichloro-2-propyl) phosphate-d10 focus on its use as an analytical standard rather than a receptor-binding agent. A standard protocol for environmental analysis involves preparing a solution of the compound in an appropriate solvent (e.g., methanol or acetonitrile) and using it as an internal standard for LC-MS/MS or GC-MS analysis. The compound is added to samples (e.g., urine, serum, or environmental water) before extraction and cleanup procedures. Quantification is performed by monitoring specific mass transitions for the labeled and unlabeled compounds. Quality control includes purity analysis (>95%) and calibration with standard solutions.
|
| Cell Assay |
Cell-based experiments are not performed with bis(1,3-dichloro-2-propyl) phosphate-d10, as it is an analytical standard rather than a test compound for biological activity. The compound is used exclusively in environmental and toxicological analysis. When studying the biological effects of organophosphate flame retardants, non-labeled compounds are used in cell culture assays. The labeled compound is not evaluated in cellular systems.
|
| Animal Protocol |
In vivo animal studies are not conducted with bis(1,3-dichloro-2-propyl) phosphate-d10. When toxicokinetic studies of organophosphate flame retardants are performed in animals, the labeled compound may be used as an internal standard for the quantification of BDCPP in plasma, urine, and tissue samples. In typical protocols, animals are dosed with TDCPP, and blood and urine samples are collected at various time points. The labeled internal standard is added to the samples before LC-MS/MS analysis to ensure accurate quantification.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of bis(1,3-dichloro-2-propyl) phosphate-d10 are not characterized, as it is not a drug substance. Its non-deuterated form, BDCPP, is a metabolite of TDCPP with a reported half-life in humans of approximately 10-15 hours. BDCPP is excreted primarily in urine. The compound is used as a biomarker to assess exposure to organophosphate flame retardants. The deuterated standard enables accurate quantification of BDCPP in pharmacokinetic and biomonitoring studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for bis(1,3-dichloro-2-propyl) phosphate-d10 are not available, as it is an analytical standard. Its non-deuterated metabolite, BDCPP, is a known urinary metabolite of the flame retardant TDCPP, which has been classified as a potential carcinogen. Studies have suggested that exposure to TDCPP and its metabolites may be associated with endocrine disruption and other health effects. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood.
|
| References | |
| Additional Infomation |
Bis(1,3-dichloro-2-propyl) phosphate-d10 is a stable isotope-labeled analytical standard used for the quantification of the organophosphate flame retardant metabolite BDCPP in environmental and biological samples. It is also known as BDCPP-d10 and 1,3-dichloro-2-propanol-d7 hydrogen phosphate. The compound is used in analytical method development, quality control, and biomonitoring studies. Its mechanism of action is analytical—serving as an internal standard for mass spectrometry-based quantification of exposure to organophosphate flame retardants.
|
| Molecular Formula |
C6H11CL4O4P
|
|---|---|
| Molecular Weight |
319.934899568558
|
| Exact Mass |
329.974
|
| CAS # |
1477495-19-4
|
| PubChem CID |
131667687
|
| Appearance |
Off-white to light brown liquid
|
| LogP |
1.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
15
|
| Complexity |
191
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])(C([2H])(C([2H])([2H])Cl)OP(=O)(O)OC([2H])(C([2H])([2H])Cl)C([2H])([2H])Cl)Cl
|
| InChi Key |
NNKRUBFJSSBFSS-MBXGXEIXSA-N
|
| InChi Code |
InChI=1S/C6H11Cl4O4P/c7-1-5(2-8)13-15(11,12)14-6(3-9)4-10/h5-6H,1-4H2,(H,11,12)/i1D2,2D2,3D2,4D2,5D,6D
|
| Chemical Name |
bis(1,3-dichloro-1,1,2,3,3-pentadeuteriopropan-2-yl) hydrogen phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1257 mL | 15.6284 mL | 31.2568 mL | |
| 5 mM | 0.6251 mL | 3.1257 mL | 6.2514 mL | |
| 10 mM | 0.3126 mL | 1.5628 mL | 3.1257 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
